novo nordisk cagrisema - Search News

Novo Nordisk shares drop

The Wall Street Journal on MSN · 1d

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an earlier study recorded 22.7%.

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.

Investopedia on MSN · 1d

Novo Nordisk Shares Sink on Latest CagriSema Weight Loss Drug Study

Key Takeaways Novo Nordisk's U.S.-listed shares fell Monday after it released the latest results for its developmental weight loss drug CagriSema.The average weight loss among those taking the new drug was 15.

GlobalData on MSN1d

Novo Nordisk’s stock drops despite CagriSema hitting goal of Phase III trial

The Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination ...

1d

Novo Nordisk reports REDEFINE 2 trial of CagriSema achieved primary endpoint

Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results